RxDecoder My Rx
‹ All drugs

amoxicillin

Sold as Moxatag. Class: Penicillins with extended spectrum. First FDA approval 01/18/1974: 52 years on the US market.

This grade answers one narrow question: how strong is the public evidence and safety record behind this drug, and how clean is its money trail and court record? It is not a verdict on whether the drug is right for you.

A

Score breakdown (91/100)

Safety ×35%
A
Evidence ×25%
C
Regulatory ×15%
B
Money & lawsuits ×15%
A
Options ×10%
A

Safety: 100

Evidence: 72

Regulatory history: 86

Money & lawsuits: 100

Options: 100

Independent reviews and post-approval warnings

WHO Essential Medicine

Listed on the WHO Model List of Essential Medicines (antibiotic stewardship group: KeyAccessGroup, AccessGroup): a global expert panel judged it among the medicines a health system should always have, on evidence of value, not marketing.

What the FDA label says

Approved uses

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin Capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: Amoxicillin Capsules are a penicillin-class antibacterial indicated for treatment of infections due to susceptible strains of designated microorganisms. Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract. ( 1.1 – 1.5 ) In combination for treatment of H. pylori infection and duodenal ulcer disease. ( 1.6 , 1.7 ) 1.1 Infectio ns of the ear, nose, and throat – due to Streptococcus species, (α- and β-hemolytic isolates only), Streptococcus pneumoniae ...

Contraindications

Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other β-lactam antibiotics (e.g., penicillins and cephalosporins). History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other beta-lactams (e.g., penicillins or cephalosporins). ( 4 ).

Warnings and precautions

Anaphylactic reactions: Serious and occasionally fatal anaphylactic reactions have been reported in patients on penicillin therapy. Serious anaphylactic reactions require immediate emergency treatment with supportive measures. ( 5.1 ) Clostridium difficile -associated diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs. ( 5.2 ) 5.1 Anaphylactic Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with amoxicillin, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. 5.2 Clostridium difficile Associated Diarrhea Clostridium ...

Adverse reactions (label)

The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see Warnings and Precautions ( 5.1 )] CDAD [see Warnings and Precautions ( 5.2 )] The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules were diarrhea, rash, vomiting, and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-233-2001 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules were diarrhea, rash, vomiting, and nausea. Triple therapy: The most frequently reported adverse events for patients who received triple therapy (amoxicillin/clarithromycin/ lansoprazole) were diarrhea (7%), headache (6%), and taste perversion (5%). Dual therapy: The most frequently reported adverse events for patients who received d...

Source: FDA SPL label for Amoxicillin (PD-Rx Pharmaceuticals, Inc.), effective 20251020. Full label on DailyMed.

Side-effect reports sent to the FDA

These are counts of reports people filed, not rates of harm. Anyone can file one, and nobody checks whether the drug was the cause. Millions of doses are taken for every report sent, so the useful part is how this drug compares with the average across all drugs.

72,134reports that mention this drug
71,907of those blame this drug, not another one the person was taking
81%of reports describe a serious outcome, such as a hospital stay (average for all drugs: 57%)
6.2%of reports include a death, from any cause (average for all drugs: 9.1%)

Problems reported most often

Chronic Kidney Disease · 4,872Acute Kidney Injury · 4,803Diarrhoea · 3,920Drug Hypersensitivity · 3,812Drug Ineffective · 3,546Nausea · 3,545Rash · 3,512Dyspnoea · 3,442Off Label Use · 3,394Fatigue · 3,215Renal Failure · 3,051Pain · 3,002Pruritus · 2,953Headache · 2,863Vomiting · 2,662

Reports per year

20192020202120222023202420252026
9,7027,8586,2465,4405,5325,4564,8382,444

1,335 reports blaming this drug for every million Medicare prescriptions filled, which is 0.5× the typical drug on this site. (12,634 reports in 2024–2026, against 9,463,530 Medicare fills in one year. This is the one number here that accounts for how many people take the drug.)

Source: the FDA's Adverse Event Reporting System (FAERS). Reports are voluntary and unverified. Drugs that are prescribed a lot, in the news, or in lawsuits attract more reports, so the percentages are compared with the whole database to correct for that partly, not fully.

Recalls and regulatory record

8recall actions on file
7 / 50brand / generic applications
10label changes since 2021
NoREMS program
DateClassFirmReason
04/2022Class IIMckesson Medical-Surgical Inc. Corporate OfficecGMP deviations: Temperature abuse
01/2022Class IICARDINAL HEALTHCARECGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
01/2022Class IICARDINAL HEALTHCARECGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
11/2016Class IIIWest-Ward Pharmaceuticals Corp.Labeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.
06/2016Class IITeva North AmericaSuperpotent drug: Out of specification test result for assay during stability testing.
06/2013Class IIITeva Pharmaceuticals USA, Inc.Discoloration: This recall is being carried out due to an orange to brown discolored Amoxicillin powder on the inner foil seal of the bottles. This is an expansion of RES 65050.
04/2013Class IIITeva Pharmaceuticals USA, Inc.Discoloration: This recall is being carried out due to a yellow to brown discolored Amoxicillin powder on the inner foil seal of the bottles.
04/2013Class IISandoz IncorporatedPresence of Foreign Substance, Sandoz is recalling certain lots of Amoxicillin Capsules, USP 500 mg due to potential contamination with fragments of stainless steel wire mesh.

Class I = reasonable probability of serious harm. Class II = temporary or reversible harm. Class III = unlikely to harm. Most generic recalls are manufacturing or labeling defects for one lot, not a verdict on the molecule.

Evidence base

814randomized trials (PubMed)
61systematic reviews
1,085registered trials
21%of completed trials posted results
7%terminated or withdrawn
16%industry-funded

Independent Cochrane reviews

Counts measure how much evidence exists and how transparent it is, not how big the benefit is. For that, ask your prescriber: if 100 people like me took this, how many would get better because of it, and how many would be harmed? (Doctors call these the "number needed to treat" and "number needed to harm.") It differs by condition and is the number drug ads leave out. Sources: PubMed, ClinicalTrials.gov.

Money and lawsuits

In 2024, drug companies reported $0 in payments to US physicians and hospitals tied to this drug across 0 transactions.

No pending federal MDL names this drug or its brands.

Not named in any federal pharmaceutical settlement of $100M or more on record.

Sources: CMS Open Payments (Sunshine Act); Judicial Panel on Multidistrict Litigation pending docket list; DOJ settlements as tabulated on Wikipedia with links to the primary record. State-court and individual suits are not included.

Who takes it and what it costs

6,486,159Medicare Part D patients (2024)
9,463,530prescriptions filled
$3average cost per fill
$29Mtotal Medicare spend

Same-class alternatives

amdinocillinamdinocillin pivoxilampicillinazlocillinbacampicillincarbenicillinhetacillinmethampicillinmezlocillinpiperacillinpivampicillinsulbenicillintalampicillintemocillinticarcillin

Same ATC pharmacological class, graded ones first, best grade at the top. Being in the same class does not make them interchangeable for your condition; it makes them worth asking about.

Questions to ask your prescriber

  1. The most-reported problems in FDA's adverse event data are chronic kidney disease, acute kidney injury, diarrhoea, drug hypersensitivity. How would we recognize and handle those?
  2. Why this one over amdinocillin, amdinocillin pivoxil, ampicillin? What would make you pick one of those instead?
  3. What result are we expecting, by when, and what is the plan if it does not happen?
  4. If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)